Acorda Therapeutics (ACOR) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Therapeutics Reports First Quarter 2021 Financial Results
May 6, 2021 4:00 PM EDTINBRIJA® (levodopa inhalation powder) Q1 2021 net revenue of $5 million; 13% increase over Q1 2020 INBRIJA organic growth (dispensed cartons) was 25% Q1 2021 over Q1 2020 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q1 2021 net revenue of $20.3 million; flat to Q1 2020
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the first quarter 2021.
We were pleased to see the increase in INBRIJA net sales in the first quarter of 2021 over the same quarter of 2020. In addition, our organic growth, measured by the... More
